Drug intelligence / Profile preview

IVMED-10

Development stage: Unknown
Lead developer: iVeena Delivery Systems
Modality: Small Molecules
Administration: Ophthalmic

Overview

IVMED-10 is a bioerodible, dexamethasone-releasing implant developed by iVeena Delivery Systems for intracapsular placement during cataract surgery. The product is designed to provide sustained release of dexamethasone, a potent corticosteroid, directly into the eye to manage post-operative pain and inflammation. By utilizing a proprietary drug delivery platform, IVMED-10 aims to eliminate the need for patient-administered anti-inflammatory eye drops following routine cataract extractions, thereby improving adherence and therapeutic outcomes. Pilot clinical trials have indicated that the implant is safe and effective, with results comparable to the current standard of care.

Other names: dexamethasone intracapsular implant

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on IVMED-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVMED-10.

Explore the full profile